Heart Failure

In clinical trials, empagliflozin significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25%.

Study examines whether dapagliflozin is cost-effective when added to standard of care for patients who have heart failure with reduced ejection fraction.

Its important for the patients with heart failure to know how much their ejection fraction is.

Ryan Jacobsen, PharmD, BCPS leads a discussion on defining heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) as well as the importance of staging and functional classification criteria.

Recently, many providers have become worried about the potential of certain medications to worsen transmission and outcomes in the setting of the global COVID-19 pandemic.

Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.

Staying on top of oral hygiene may be connected to a lower risk of atrial fibrillation and heart failure.

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.

The PHARM-CHF trial investigated whether regularly seeing a pharmacist improves adherence to heart failure medications.

Top news of the day from across the health care landscape

“The central problem in heart failure is not that patients are short of breath or retain fluid. The problem is that they die.”

The findings of a retrospective study suggest that timing of heart failure (HF)-related pharmacotherapy following a HF-related encounter has potential implications on subsequent healthcare costs.

This may be the first drug shown to reduce mortality in the HFpEF population in the United States but will hopefully not be the last.

A number of landmark clinical studies on lipid lowering and cardiovascular health have been published, shaping how patients are treated.

Large clinical trial shows no increase in adverse events from treatment with aspirin for heart failure.

Even small weight gain may change the structure of the heart.

While overall hospitalizations for heart failure decreased, problems persist among minority populations.

This article highlights 5 published case reports that document unusual drug overdoses.

Investigational cancer drug blocks inflammation and fibrosis in heart cells.

Beta blockers may be unnecessary for patients who experienced a heart attack and did not develop heart failure.

Many cases of congenital heart disease go undetected until adulthood, and are discovered after heart failure develops or an arrhythmia causes sudden cardiac death.

During the last 4 decades, the epidemiologic characteristics of acute myocardial infarction have changed.

Dysbiosis of gut bacteria is a factor in several diseases, possibly including heart failure.

Data are limited about the safety of and effects of exercise on patients heart failure with atrial fibrillation.

Study examines whether treating systolic blood pressure of more than 120 mmHG reduces the risk of acute decompensated heart failure.

Many patients have low adherence to statins more than 2 years after a heart attack.

Atrial fibrillation is also more commonly the etiology behind stroke in women than in men.